The company gamete (see Start-ups in the race for artificial gametes) announced “ the first live human birth » obtained from oocytes matured in vitro using a technique called Fertile which uses induced pluripotent stem (iPS) cells (see Iris: first French baby born after MIV (in vitro maturation of the oocyte))[1]. The delivery took place at the Santa Isabel Clinic, in Lima, Peru.
Unlike PMA methods “ traditional ”, which are based on hormonal stimulation “ at high dose » for 10 to 14 days to mature the oocytes, the technology Fertile uses “ young modified ovarian support cells » to recreate the natural process of oocyte maturation in the laboratory. This procedure makes it possible to replace 80% of the hormone injections necessary for IVF “ traditional » and reduces the duration of treatment cycles to “ only three days ».
« This milestone marks a turning point in reproductive health and highlights the first application of iPSC technology in IVF and the immense potential of our technology “, boasts Dr. Dina Radenkovic, CEO and co-founder of gamete.
For the moment, the marketing of Fertile was authorized in Australia and “ in major Latin American markets ».
[1] Scientists published on this technique in 2023 in the journal Human reproduction: Sabrina Piechota et al., Human-induced pluripotent stem cell-derived ovarian support cell co-culture improves oocyte maturation in vitro after abbreviated gonadotropin stimulation, Human ReproductionVolume 38, Issue 12, December 2023, Pages 2456–2469, https://doi.org/10.1093/humrep/dead205
Source : AP news (16/12/2024)
Health
